Drug Trial Radar · NCT06659549
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Jan 10, 2025
Primary completion
Mar 30, 2028
Study completion May 30, 2028
Sponsor
- Lead sponsor
- Galimedix Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.
Conditions
- Geographic Atrophy of the Macula
Interventions
GAL-101Drug
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
PlaceboDrug
Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.Time frame: From baseline to last on-treatment visit (48 up to 96 weeks)
Locations
24 sites in 8 countries. Site status is shown where the registry gives one.
Retina-Vitreous Associates Medical Group
Beverly Hills, California · Recruiting
Bay Area Retina Associates
Walnut Creek, California · Recruiting
Cumberland Valley Retina Consultants
Hagerstown, Maryland · Suspended
Ophthalmological Center After S.V. Malayan
Yerevan, Armenia · Recruiting
Centre Rétine Gallien
Bordeaux, France · Recruiting
Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
Lyon, France · Recruiting
Centre Monticelli Paradis d'Ophtalmologie
Marseille, France · Recruiting
Centre Ophtalmologique Odéon
Paris, France · Recruiting
Centre médico-chirurgical de Touraine
Tours, France · Recruiting
Akhali Mzera Limited
Tbilisi, Georgia · Recruiting
Caucasus Medical Centre LLC
Tbilisi, Georgia · Recruiting
Universitäts-Augenklinik Bonn
Bonn, Germany · Recruiting
Universitätsklinikum Freiburg Klinik für Augenheilkunde
Freiburg im Breisgau, Germany · Recruiting
Medizinische Hochschule Hannover Augenklinik
Hanover, Germany · Recruiting
Dietrich Bonhoeffer Klinikum
Neubrandenburg, Germany · Recruiting
Universitätsklinikum Tübingen, Department für Augenheilkunde.
Tübingen, Germany · Recruiting
UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
Ulm, Germany · Not yet recruiting
UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
Kildare, Ireland · Recruiting
Institute of Eye Surgery (IOES Waterford)
Waterford, Ireland · Recruiting
Hadassah Medical Center
Jerusalem, Israel · Recruiting
Tel Aviv Medical Center
Tel Aviv, Israel · Recruiting
Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
Milan, Milano, Italy · Recruiting
Unità di Oculistica, IRCCS Ospedale San Raffaele
Milan, Milano, Italy · Recruiting
UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
Roma, Roma, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.